Findings showed that pembrolizumab plus chemotherapy reduced the risk of death by 17% compared with chemotherapy alone. The Food and Drug Administration (FDA) has approved Keytruda ® (pembrolizumab) ...

Keytruda, combined with gemcitabine and cisplatin, is approved for advanced biliary tract cancer, showing a 17% reduction in death risk compared to chemotherapy alone. The KEYNOTE-966 trial indicated ...

Bile duct cancer is classified by location: intrahepatic, perihilar, or distal, influencing symptoms and treatment options. Diagnosis involves blood tests, imaging, endoscopic procedures, and biopsy ...

Credit: Getty Images. The sBLA is supported by data from the KEYNOTE-966 trial. The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for ...

Rachna T. Shroff, MD, addresses the impact of health disparities in the treatment outcomes of patients with cancer. Specifically discussing patients with biliary tract cancer, Dr Shroff focuses ...

Please provide your email address to receive an email when new articles are posted on . Gemcitabine and cisplatin plus durvalumab, with or without tremelimumab, produced favorable outcomes as ...

Acute cholangitis is a severe, bacterial infection of the biliary tract precipitated by an obstruction that often results in systemic inflammation and, in some cases, life‐threatening sepsis. This ...

The US Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for locally advanced unresectable or metastatic biliary tract cancer in combination with gemcitabine and cisplatin.

Please provide your email address to receive an email when new articles are posted on . Researchers reported a 41% confirmed ORR among patients with HER2-positive disease. No patients with ...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented final results from the Phase II SUMMIT ‘basket’ trial, assessing the efficacy of neratinib ...

Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The "Biliary Tract Cancer Market With Impact Analysis of US Tariffs (2025 Edition)" report has been added to ResearchAndMarkets.com's offering. This report ...